XGN Exagen

Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021

Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (844) 826-3033 (U.S.) or (412) 317-5185 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at

A replay of the conference call will be available until Wednesday, November 17, 2021 at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 10161457. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit .

CONTACTS:

Investor Relations

Exagen Inc.

Ryan Douglas

 

760.560.1525

Company

Exagen Inc.

Kamal Adawi, Chief Financial Officer

 

760.477.5514



EN
27/10/2021

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Participate in Upcoming Investor Conferences CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation: Investor meetings and fireside chat at 3:00 p.m. ET Roth Capital Conference – Laguna Niguel, CA Date: March 23, 2026 Participation: Investor meetings About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune ...

1h / 38m 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Re...

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890Inter...

February 24, 2026 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results  Revenue  Three Months EndedDecember 31, 2025 Twelve Months EndedDecember 31, 2025Total Revenue$16M to $17M $66M to $67MYear-Over-Year Growth17% to 24% 19% to 20%  Other  Twelve Months EndedDecember 31, 2025...

January 11, 2026 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. to Participate in Fourth Quarter Investor Conferences CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 Location: Sheraton New York Times Square Hotel Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: November 20, 2025 Location: Westin NY Grand Central - 212 E 42nd Street New York, NY 10017 About Exagen...

November 11, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Inc. Reports Strong Q3 2025 Results CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,2...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch